Patent
Vaccine formulation against Gumboro disease
TLDR
The multivalent polynucleotide vaccine for birds comprises >= 3 valencies (i.e. it provides protection against >= 3 avian pathogens), each valency consisting of a plasmid able to express in host cells in vivo >= 1 of the specified antigen genes from one of the following pathogens: (a) Marek's disease virus gB and gD genes; (b) Newcastle Disease virus HN and F genes;(c) Gumboro disease virus VP2 gene, and (d) avian infectious anaemia virus C + NS1 genesAbstract:
Multivalent polynucleotide vaccine for birds comprises >= 3 valencies (i.e. it provides protection against >= 3 avian pathogens), each valency consisting of a plasmid able to express in host cells in vivo >= 1 of the specified antigen genes from one of the following pathogens: (a) Marek's disease virus gB and gD genes; (b) Newcastle Disease virus HN and F genes; (c) Gumboro's disease virus VP2 gene, and (d) avian infectious anaemia virus C + NS1 genes.read more
References
More filters
Patent
Infectious bursal disease virus recombinant poxvirus vaccine
TL;DR: In this paper, a recombinant poxvirus, such as fowlpox virus, containing foreign DNA from infectious bursal disease virus, was described for inducing an immunological response in host animals inoculated with the vaccine.
Patent
Production of ibdv vp2 in highly immunogenic form
Ahmed Azad,Ian G. Macreadie,Neil M. McKern,Paul R. Vaughan,Mittur N. Jagadish,Kevin J. Fahey,Antony James Chapman,Hans-Georg Heine +7 more
TL;DR: A highly immunogenic form of the VP2 structural protein of IBDV comprises a high molecular weight aggregated form of VP2 produced by the expression of a nucleotide sequence coding for the VP 2 structural protein or a polypeptide displaying the antigenicity of all or a part of the structural protein in a yeast or other eukaryotic host cell as discussed by the authors.
Patent
Recombinant avian adenovirus vector
TL;DR: In this article, a recombinant vector comprising of recombinant avian adenovirus incorporating, and capable of expression of at least one heterologous nucleotide sequence is described.
Patent
Avian recombinant live vaccine
Jean-Christophe Audonnet,Michel Bublot,Raphael Jean Darteil,Carole Veronique Duinat,Eliane Louise Françoise Laplace,Michel Albert Emile Riviere +5 more
TL;DR: An avian recombinant live vaccine including, as the vector, a Marek's disease virus, particularly HVT, including at least one nucleotide sequence coding for and expressing an antigenic polypeptide of an avian pathogen, and being inserted into the UL13 gene under the control of the immediate early CMV promoter is described in this paper.
Patent
Turkey herpesvirus vector as a recombinant infectious bursal disease vaccine
TL;DR: A recombinant turkey herpesvirus (HVT) containing coding sequences of infectious bursal disease virus structural proteins, and characterised in that it contains, at a site in its genome, at least one sequence coding for a protein selected from the group consisting of proteins VP2 and VP3 under conditions suitable for the expression of said sequences and the production of said protein this article.